Introduction {#S1}
============

Mitochondria are organelles found in eukaryotic cells that have an important role in the maintenance of homeostasis and tissue health. Mitochondria can produce up to 95% of all ATP in the cell and sustain metabolic processes such as the tricarboxylic acid cycle (TCA), beta-oxidation, calcium regulation, protein synthesis, among others ([@B90]; [@B58]; [@B153]; [@B14]). They also play a major role in inducing cell differentiation, sustaining proliferation, maintaining cell survival, and triggering apoptosis, all of which are essential for the development and maintenance of an organism in time ([@B155]; [@B105]). Mitochondrial dysfunction increases as age progresses. This organelle accumulates damage with age and through the constant exposure to external factors, like ultraviolet radiation (UVR), which harms its function and genetic patrimony ([@B103]; [@B19]). The presence of dysfunctional mitochondria has been associated with neurological and degenerative disorders, obesity, type 2 diabetes, and cancer ([@B4]; [@B113]; [@B22]).

The skin is the largest organ in the human body, serving as our connection to the environment and protecting us from diverse stressors. A variety of environmental factors affect the skin, inducing either a positive or negative response. Ultraviolet radiation induces positive changes in our physiology through skin sensing and reactions ([@B141]). Other factors, such as pollutants and microbial insults, contribute to skin aging and decrease the functionality of the skin ([@B16]). The neuroendocrine messengers produced after UVR exposure include neuropeptides, biogenic amines, serotonin, and melatonin. These stimulate the hypothalamus, pituitary gland, and adrenal glands (HPA axis), causing effects in our mood, immune system, and behavior ([@B136]). In skin cells, UVR induces the release of neuro-endocrine-immune messengers into the circulation to maintain homeostasis, leading to melanogenesis and keratinocytes proliferation ([@B39]; [@B141]; [@B136]). The skin mitochondria play an important role in supporting these processes, as they are an essential factor in the maintenance of skin health ([@B141]; [@B138], [@B140]). Excess of UVR, pollutants, microbial insults, and wounds can accumulate with time in the skin, causing loss of functionality and cosmetic appearance ([@B141]; [@B12]; [@B62]). Skin and its cells' mitochondria are highly susceptible to detrimental environmental factors. Ultraviolet radiation causes mitochondrial DNA (mtDNA) deletions, perturbing the electron flow, and energy production ([@B80]). Treating mitochondrial damage would help to mitigate the cumulative damages caused by environmental factors.

Mutations related to monogenic mitochondrial disorders can cause fragmentation of the mitochondrial network in the cell. Affecting this network hampers its capacity to maintain mtDNA stability. When good and damaged mitochondria are unable to fuse within networks, they can't exchange healthy mtDNA or get rid of damaged DNA copies. This ultimately leads to dysfunctions in the cell and premature senescence ([@B77]). For instance, patients with fibromyalgia suffer from oxidative stress and inflammation of the skin which has been linked to mitochondrial dysfunction ([@B121]). Healthy skin depends on the maintenance of functional mitochondria, which could be a target for the development of medical and cosmetic anti-aging treatments.

To our knowledge, there is no effective treatment available to the public to reverse skin aging by targeting mitochondria. The few existing therapeutic options focused on the mitochondria are under development and still, need further *in vitro* assays and clinical validation ([@B80]; [@B154] -- Methods for retarding the effects of aging of the skin -- Google Patents; [@B5]). In addition, no available products, including topical application of natural substances and antioxidants, offer a substantial recovery from many skin aging symptoms such as mtDNA instability, respiration, collagen production, neovascularization, and localized inflammation ([@B80]).

In this hypothesis article we present the idea and arguments of using the artificial mitochondria transfer/transplant (AMT/T) technique as a possible skin anti-aging therapeutic. We interpret recent data and findings regarding the use of the AMT/T to repair cells and tissue damage. It has been observed previously that the use of AMT/T *in vitro*, *in vivo*, and clinically promotes cell and tissue recovery in different diseases, with effects that could be used to repair skin damage. For example, MitoCeption, one of many AMT/T techniques, induces cell proliferation, migration, and increased respiratory ATP production, processes needed to repair the damage in aged skin ([@B21]). PAMM MitoCeption (Primary Allogeneic Mitochondria Mix Transfer by MitoCeption) repaired UVR damaged cells by recovering the loss of metabolic activity, mitochondrial mass, mtDNA sequence stability in addition to decreasing p53 expression ([@B19]). Published data provided evidence that syngeneic or allogeneic AMT/T transfer of mitochondria was not immunogenic, and additionally that AMT/T to proinflammatory cells, such as TH17, induced cell conversion to Tregs and promoted immune regulation ([@B84]; [@B117]). Beyond *in vitro* applications, AMT/T showed to have regenerative effects *in vivo*, in diseases such as heart and brain ischemia. AMT/T applied clinically to pediatric patients with myocardial dysfunction has also shown positive results on ischemic injured tissues ([@B83]; [@B33]; [@B93]; [@B41]). Our hypothesis regarding AMT/T as an antiaging skin therapeutic could be tested *in vitro*, *in vivo*, and clinically, to promote the applications of this technique. The possibility to transfer new mitochondria to senescent or age-induced harmed cells in the skin could represent a plausible option to treat the effects of aging.

Skin Aging and Mitochondria {#S2}
===========================

Cutaneous aging is a complex and continuous biological process that depends on intrinsic (genetic) and extrinsic factors. These factors contribute to approximately a 50% alteration in skin function when arriving to midlife ([@B157]). Physiologically, the skin undergoes constant changes, with the capacity to repair and renovate its constituents after damage. Despite this, environmental factors, biological and chronological aging, all hamper the skin's abilities to maintain homeostasis and repair.

Genetic or intrinsic features that trigger aging are inevitable. It is possible to observe histologic changes that are subtle when we become old, but with the years the loss of function becomes evident. Histologically, skin aging results in a flattening of the dermoepidermal junction, a smaller amount of epidermal cell turnover, and a decrease in the number of Langerhans cells with advance age ([Figures 1A,B](#F1){ref-type="fig"}) ([@B35]; [@B46]). The dermis becomes atrophic because it has a less dense intercellular matrix caused by a decrease in the number of fibroblasts and collagen fibers. As time goes on, collagen fibers become thinner, and after 50 years the thinner fibers start to fragment and progressively experience lysis. This also occurs with elastin fibers, but at a different rate ([@B158]).

![**(A)** Skin structure, cells, and energetic status. The skin is divided in three major cell layers: epidermis, dermis, and hypodermis. The epidermis is the outer layer composed by cells derived from basal stem cells keratinocytes that differentiate, proliferate, and migrate to the surface. The Keratinocytes stem cells are long-lived with a glycolytic metabolism. The proliferating keratinocytes are short-lived with active mitochondria. The Merkel, melanocyte, and Langerhans cells are long-lived and highly dependent of mitochondria function. **(B)** Cutaneous aging is triggered by intrinsic and extrinsic factors that could be treated with AMT/T Skin aging results in the flattening of cell layers and a decrease on cell turnover. This process is accompanied by the decrease of mitochondria function. Time and the environmental damage accumulates, worsening the loss of skin functionality greatly affecting the mitochondria, generating mtDNA mutations, and the increase of ROS production. It would be possible to treat skin aging by AMT/T administered by microneedles or microemulsions. Mitochondria can be delivered to the epidermis possibly resulting in the reconstitution of cellular functionality cell turnover and proliferation. Figure created with [BioRender.com](http://www.BioRender.com).](fbioe-08-00919-g001){#F1}

There is evidence of decreased collagen production in the skin, correlating it with the severity of UVR damage and other factors ([Figures 1A,B](#F1){ref-type="fig"}). In the papillary dermis, a loose meshwork of type I and type III collagen fibers has been observed, where type III collagen becomes more abundant in the adventitial dermis ([@B94]; [@B98]). Immunofluorescence studies have shown an increase of collagen I and a decrease of collagen III during the aging process ([@B35]). As an individual ages, the dermis gradually replaces the loose meshwork of collagen (type III) with well-distributed dense collagen fibers (type I) ([@B158]).

A 10 to 20% reduction of melanin per decade has been observed. Is not clear if this reduction is a consequence of a decreased number or a loss of function of melanocytes ([Figures 1A,B](#F1){ref-type="fig"}) ([@B118]). Extrinsic factors including, but not limited to, sun exposure, cigarette exposure, bad nutrition, and low water intake have been seen to induce a process called elastosis. During this processes many aging processes are observed including epidermal atrophy, collagen and elastin fiber fragmentation, and elastin deposition by histopathology ([@B70]). These extrinsic factors, in addition to the loss of collagen, decreases the overall strength of the skin, favors wrinkle formation, and creates a microenvironment that facilitates tumorigenesis and progression ([@B35]).

The skin joins together various systems with different energy demands to perform its protective function ([@B38]). The immune, pigmentary, epidermal, dermal, vascular, and adnexal systems are together and interact in the skin ([@B140]). Here, the mitochondria plays a major role in providing the energy support necessary to maintain all systems working. Mitochondria function in the skin could be divided into three major categories: energy, homeostasis, and growth ([@B144]). Energy consumption and metabolic activity could be classified as proposed by [@B38], suggesting long-lived stem cells with a low metabolic activity, short-lived differentiating cells with a high metabolic activity (such as keratinocytes), and long-lived differentiated cells with high metabolic activity such as Merkel cells ([@B38]). Interestingly, epidermal keratinocyte stem cells are maintained in a regular number throughout life ([@B48]) and depend on anaerobic glycolysis ([@B55]). Later, these cells and their mitochondria are activated, inducing the differentiation process and proliferation of keratinocytes ([@B55]). Merkel cells and melanocytes need healthy mitochondria to perform their roles in the skin. Mitochondrial malfunction malfunction leads to reactive oxygen species (ROS) production mecanosensoring decrease, decrease melanin synthesis, and senescence ([@B38]; [@B53]). Mutations in mitochondrial repair genes and haem production have been associated with several skin aberrations such as lipomas and pigmentation disorders ([@B144]). Wound healing and hair growth are also part of the physiological functions of the skin where mitochondria support the optimal regeneration and differentiation, respectively ([@B144]).

In the skin and other organs, damage in mtDNA increases with age ([Figure 1B](#F1){ref-type="fig"}). Specific mutation patterns have been reported for skin cell mitochondria DNA, or more specifically, for its promoter (T414G transversion). This mutation has been also found in other aging tissues, such as the muscle and colon. Studies on skin samples have shown that mtDNA damage is correlated with oxidative stress, especially in exposed skin areas to UVR, such as the face and hands ([@B62]). In these areas of increased sun exposure, Ray et al. found more epidermal skin mtDNA deletions in comparison to other less exposed areas. Furthermore, aged human fibroblasts have shown a raise in point mutations, meaning that different forms of mtDNA damage contributes to skin aging ([@B96]). The increase of 4977bp and 3895 bp deletion have been associated with skin age, it has been observed in the dermis of older individuals with excessive sun exposure ([@B43]; [@B114]). As documented by several studies, the oxidative stress induced by UVR \[Ultraviolet Radiation Type A (UVA) and Ultraviolet Radiation Type B (UVB)\] produces alterations in the dermis, specifically in the DNA. The damage increases the mitochondrial dysfunction which will produce more ROS ([Figure 1B](#F1){ref-type="fig"}) ([@B62]). In consequence, many studies take the mtDNA as a skin aging marker, typically caused by UVR.

Time and external factors definitely affect the mitochondria and mtDNA ([Figure 1B](#F1){ref-type="fig"}). It has been shown that hydrocarbons such as cigarette smoke and particulate matter (PM) are toxic to mitochondria and increase ROS production ([@B95]). The information presented in this article and in other studies highlights that besides the increase in mtDNA mutations, there is a decrease in its content producing dysfunctions in the oxidative phosphorylation process. Interestingly, modifying the mtDNA polymerase γ (POLG1) in a mouse induced the mtDNA depletion mimicking the phenotypic changes related to aging and less activity of OXPHOS complex. The first changes were related to hair loss (alopecia), wrinkles, hyperkeratotic and hyperplastic epidermis, dermal inflammation, and acanthosis ([@B127]). These characteristics are comparable to aged human skin, which has leathery, increased laxity, uneven pigmentation, and brown spots ([@B62]). After restoring mtDNA ([@B127]), mice have been shown to recover most of its normal phenotype. With this information, the possibility to replenish the defective mitochondrial content of aged cells in the skin by AMT/T could represent a viable option to restore healthy mtDNA copies and new functional mitochondria.

The AMT/T Technique {#S3}
===================

The mitochondria transfer between cells has been studied *in vitro* and *in vivo* and associated with cell repair or improvements in cellular physiology ([@B107]). Among all cells that have the capacity to transfer mitochondria, mesenchymal stem/stromal cells (MSCs) have shown to induce remarkable properties by this process. Mesenchymal stem/stromal cells are able to transfer mitochondria to different cell types, including damaged cells, cancerous cells, and lung cells. They have shown positive effects reflected in cell repair, gain of function, and improving the cell's overall energetics ([@B63]; [@B21]). In another example, astrocytes are able to exchange mitochondria as a key factor for neuron survival in a mouse model. After stroke, injured neurons release mitochondria, which are collected and recycled by astrocytes. In return, astrocytes share healthy mitochondria to neurons in order to enhance their recovery ([@B57]). Cells naturally exchange mitochondria as repairing mechanisms. This process has inspired the development of new therapies, some of which have been developed by several researchers and are currently used *in vitro*, *in vivo*, and in clinical applications ([@B41]; [@B49]; [@B19]).

The use of mitochondria as a therapeutic agent by artificial mitochondria transfer/transplant (AMT/T) is gaining more evidence of its regenerative effects from *in vitro* to *in vivo* approaches, treating ischemic diseases in the majority of cases ([@B21], [@B20]; [@B41]; [@B19]). This process aims to use mitochondria to repair damaged cells and tissue, alone or as a complement to current standards of therapy. AMT/T could be applied to enhance proliferation, migration, tissue regeneration and stress resistance of recipient cells ([@B21]; [@B81]; [@B41]; [@B19]). *In vitro*, [@B31] were the first to show that AMT/T is able to effectively transfer antibiotic resistance coded by the mtDNA to sensitive mammalian cells when they received exogenous mitochondria ([@B72]). [@B72] showed that reinjecting isolated mitochondria in mitochondria depleted mammalian cells can restore energy production based on respiration.

Since the first assays of AMT/T, different approaches have been developed in order to improve and simplify this process. Among the most common, are those related to chemical agents or physical adaptations to facilitate the transfer ([@B73]; [@B81]; [@B69]; [@B27]; [@B19]). Most of these methods are restricted to *in vitro* applications, however, it could be advantageous to transfer mitochondria to specific cells (*ex vivo* AMT/T) and reintroduce them back in the organism. Additionally, it could be a viable option to first isolate mitochondria and then modify them by coating or encapsulating them within membranes or vesicles. This could improve their internalization when applied in situ or systemically to treat an affected tissue.

As mitochondria have an important role in cell survival, transferring or transplanting them from healthy cells or tissue to damaged sites in the body has emerged as a rising therapeutic option. McCully's team in 2018 was the first to use mitochondrial transplantation on human beings. His team transplanted respiratory competent mitochondria into ischemic injured tissues in pediatric patients with myocardial dysfunction. Indeed, ischemia-reperfusion induces loss of viable mitochondria, decreases ATP production, and leads to myocardial hypoxemia and necrosis. McCully and his team treated five children, three females and two males of different ages (4 days, 6 days, 25 days, 6 months and 2 years). All of them were suffering from congenital cardiac malformations and during surgery they endured ischemia-reperfusion damages requiring extracorporeal membrane oxygenation (ECMO), which is a mechanical circulatory support. Children were eligible for mitochondrial transplantation if they already had a recent cardiac surgical procedure preceding an acute onset of coronary artery obstruction. During a second intervention, they were injected with isolated autologous healthy mitochondria directly into the myocardium affected by ischemia which was identified by echographic hypokinesis. The outcome was an improvement of global cardiac function, regional myocardial hypokinesis, and mortality. Four patients improved their left ventricular function, but two out of five died: the first, despite myocardial function improvement, showed failure in other organs and the second one died because of respiratory issues. Given the small number of patients and lack of a control group, it is difficult to attribute the effects of improvement in ventricular function to mitochondrial transplantation ([@B41]; [@B40]). However, their study shows that this technique may be expanded to treat other forms of myocardial ischemic injuries or organs damaged by ischemia-reperfusion. It is also recommended a prospective clinical trial to assess the safety, efficacy, and optimal dosing of mitochondria for clinical use ([@B41]; [@B40]).

AMT/T Applications to Treat Tissue Damage {#S4}
=========================================

Artificial mitochondria transfer/transplant has so far shown positive effects in cellular and tissue repair, and recent literature highlights its potential medical use. Many types of diseases or damaged associated conditions could be treated with AMT/T. Most of them are related to ischemic events, metabolic conditions, aging degeneration, and inflammatory associated diseases ([@B82]; [@B63]; [@B89]; [@B41]). Conditions involving cardiovascular diseases treated with AMT/T *in vivo*, *in vitro*, and in humans have been widely studied ([@B91]; [@B89]; [@B68]; [@B40]). Other promising therapeutic targets of AMT/T are neurodegenerative diseases, spinal cord injury ([@B67]), and mitochondria hereditary conditions ([@B28]; [@B50]; [@B49]). AMT/T's ability to repair damaged cells and renew the mitochondrial pool has changed the view of the mitochondria as a powerhouse of the cell to a therapeutic agent and a key element in regenerative medicine.

Important advances have been evidenced, especially *in vivo*, regarding the application of AMT/T after cardiovascular ischemic events with healthy autologous or allogeneic mitochondria. These assays have shown that AMT/T repairs the damage in the affected tissue and favors the recovery of mitochondria functions ([@B91]; [@B89]; [@B68]; [@B124]; [@B40]). Most of the time, ischemic cardiovascular diseases are the result of a lack of oxygen carrying blood reaching tissues. Ischemia alters mitochondrial function inducing ROS generation, decreasing ATP production, promoting cellular stress, and leading to apoptosis ([@B30]; [@B66]). AMT/T could be a promising cardioprotective or therapeutic treatment, if injected into infarcted areas. For example, it has been observed that AMT/T could prevent ischemia-reperfusion injury. Autologous mitochondria injections in ischemic induced lesions in rabbits' hearts enhanced oxygen consumption, cell viability, and post-infarct cardiac function. It was shown that transplanted mitochondria are quickly internalized by cardiac cells, helping to restore normal energy synthesis ([@B89]).

Other studies showed benefits of mitochondria transfer in heart ischemia *in vivo*. Myocardial ischemia was induced in pigs where autologous mitochondria were injected directly into the ischemic region for the tested group while the control group did not receive any treatment, only a vehicle. Assessment of the ischemic markers showed a significant increase in cardiac troponin I and creatine kinase levels in the control compared to the tested group, suggesting a better post-ischemic myocardial function after AMT/T ([@B33]; [@B68]). It has been shown that the delivery of mitochondria through the coronary vasculature protects the ischemic myocardium. As part of this study, rabbits' hearts were exposed to 30 min of ischemia and then 10 and 120 min of reperfusion. Mitochondria were either injected in the ischemic region or delivered by vascular perfusion through the coronary arteries at the beginning of the reperfusion procedure. Mitochondria were found near the site of delivery in the in situ administration, however, vascular perfusion had better dispersion through the heart and better protective effects after 10 and 120 min reperfusion ([@B33]).

Heart transplant is a procedure that involves keeping a donor's heart preserved outside the body until it is received by the patient. During the process the donor's heart passes, in the first instance, through cold ischemia time (CIT), which is about 4--6 h for humans. Cold ischemia time starts after cutting circulation and putting the organ in a cold transport solution. Then the transplanted heart is connected to the patient's circulation where ischemia reperfusion (IR) can cause injury as well. It has been shown that CIT causes IR injury to the heart mitochondria affecting myocardial function and tissue viability. Heterotopic heart transplantation was performed in mice and AMT/T was delivered in the coronary arteries before and after CIT. The experiments showed that mitochondrial transplant enhances heart function, decreases tissue injury, and reduces cold graft failure, thus improving the transplantation success after prolonged CIT ([@B101]).

Stroke or "brain attack" is a neurovascular disease whose characteristics and consequences could be treated with AMT/T. A decreased blood flow induces ischemia in specific regions of the brain, leading to oxygen and nutrient deprivation and causing tissue death. Mitochondria function and dynamics are particularly damaged, especially regarding its capacity to maintain the respiratory chain proton gradient and produce ROS. This leads to further structural damage, apoptosis, cell degradation, and inflammation ([@B126]; [@B104]; [@B160]). Stroke can affect specific brain areas, damaging memory, muscle control, or inducing visual loss ([@B125]; [@B60]; [@B150]). Testing the possibility to repair the loss of healthy mitochondria due to stroke by AMT/T has shown so far to improve recovery in preclinical assays. It has been observed that the use of xenogeneic mitochondria from hamsters to treat acute injurious ischemic stress in the central nervous system by AMT/T resulted in enhanced neuronal survival and recovery of motor activity ([@B61]).

Neurodegenerative diseases including Parkison's, Alzheimer's, and Huntington's are characterized by the progressive loss of neurons and induced death related to protein aggregation and inclusion body formation in cells ([@B119]; [@B78]). Together with these factors, mitochondria dysfunction seems to play an important part in the progression of these diseases. Parkinson's disease (PD) is mainly due to a progressive degeneration of dopaminergic neurons, located in the substantia nigra ([@B100]; [@B29]). Lack in dopamine secretion causes symptoms such as tremor, akinesia, and muscular hypertonia. Parkinson's progression is linked to misfolding and aggregation of α-synuclein. It has been reported that a type of α-synuclein aggregate, smaller and distinct in its conformation, called pα-syn^∗^, is particularly affecting mitochondria, causing its damage and mitophagy ([@B51]). As mitochondria is affected in Parkinson, it has been proposed to treat the disease with AMT/T. It has been observed in a PD-mice model that AMT/T led to an increase in the striatal mitochondrial activity and ATP production, a decrease of ROS levels, and improvements in Parkinson's symptoms ([@B123]). Parkinson's disease-induced rats treated with AMT/T showed that allogeneic mitochondria transplantation improves their motor activities, and pointed out a substantial decrease in dopaminergic neuron loss ([@B28]). Understanding how AMT/T can improve PD could open new treatments for this disease including using it together with current therapeutic options. Parkinson's disease is not the only neurodegenerative pathology that could be treated by AMT/T. Literature also discussed the role of mitochondria in Huntington disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Friedreich's Ataxia, highlighting the potential application of AMT/T in rare neurodegenerative pathologies ([@B82]; [@B71]; [@B23]). There is a scientific and clinical need to perform more studies where AMT/T could be used as a treatment for neurodegenerative diseases.

The exposure to toxic substances could induce liver mitochondrial dysfunction, leading to a diverse array of acute or chronic injuries ([@B36]; [@B52]). Acetaminophen-induced liver injury causes mitochondrial oxidative stress, worsening the disease ([@B159]). Toxins, such as ethanol and a variety of drugs, can impair beta-oxidation directly or through affects mitochondrial function. Mitochondrial dysfunction leads to abnormal permeability transitions, initiating hepatocyte apoptosis and necrosis ([@B111]; [@B122]). AMT/T was used to treat the damage induced by Acetaminophen liver failure by paracetamol intoxication. Mitochondria were isolated from human hepatic cells and injected intravenously in mice injured liver. After mitochondria administration, transaminase activity significantly decreased, indicating that exogenous mitochondria were protecting cells against toxicity. Mitochondria spread in several tissues and increased hepatocyte energy production, reduced ROS levels, and improved tissue regeneration ([@B47]; [@B122]). This study suggests that AMT/T may prevent acetaminophen-induced liver injury.

From the first assays of AMT/T by Clark and Shay in 1982 to the clinical application of mitochondria by McCully's team in 2018, there is strong evidence showing that receiving exogenous healthy mitochondria by damaged cells or tissues help them to recover ([@B31]; [@B20]; [@B41]). Not only does AMT/T improve tissue recovery but it also has been shown to promote immune regulation. It has been observed that syngeneic or allogeneic mitochondria delivered by intraperitoneal injection in mice does not cause an immunogenic reaction, thus opening the possibility to use mitochondria from different donors to heal damaged tissue ([@B117]). It has been shown that AMT/T has important intracellular consequences leading to short-term improvement of bioenergetics and a "supercharged" state. However, the resulting state disappears over time ([@B3]). These work together with the use of AMT/T to turn TH17 cells into Tregs promoting an immune regulatory effect. Also, the use of PAMM to repair the UVR damage of mitochondria supports the hypothesis of the possible use of mitochondria, from different donors, like PAMM to treat skin aging.

AMT/T for the Antiaging Use of Mitochondria {#S5}
===========================================

The skin is a mixture of different layers of cells working together with the immune, nerve, and vascular systems. Aging affects all skin components differently, but the transfer of healthy mitochondria could be a viable option to repair skin cell senescence and loss of function. Skin contains sets of cells with different viability during time and energy consumption. Epidermal keratinocytes stem cells and other stem cells have a long period for permanence in skin and are very susceptible to damage ([@B108]; [@B38]). Keratinocytes are cells that have a short lifespan and high metabolic activity and needs ([@B38]). Cells such as Merkel and melanocytes are long-lived and have a high metabolic activity, prompting them to accumulate damage with time ([Figure 1B](#F1){ref-type="fig"}) ([@B38]). Among these cells, fibroblasts, keratinocytes, immune cells (such as Langerhans, mechanoreceptors), as merkel cells and melanocytes, are all susceptible to aging and its damaging effects ([@B116]; [@B15]; [@B151]; [@B65]). However, all these cells have the potential to internalize mitochondria and be repaired. It has been shown that cells *in vitro* and *in vivo* are capable of uptaking mitochondria by different and active mechanisms like macropinocytosis and actin dependent internalization ([@B73]; [@B106]). Once inside, it seems that isolated mitochondria fuse with the endogenous mitochondria by the activity of mitofusins MFN1, MFN2 on the outer membrane and OPA1 on the inner membrane ([@B2]; [@B34]). The understanding of the energetic and survival fate of exogenous mitochondria inside the recipient cells is moving forward, however, important questions are still unanswered. So far the energetic boost and possibly renewal of the endogenous mitochondria pool could explain part of transfer/transplant regenerative properties ([@B3]).

It has been reported that keratinocytes and fibroblasts accumulate mtDNA mutations after UVR exposure, increasing its biological aging and stress ([Figure 1B](#F1){ref-type="fig"}) ([@B75]; [@B13]; [@B110]; [@B24]; [@B109]). These cells could internalize mitochondria, repairing their viability and providing an "energetic boost" in the basal membrane ([@B75]; [@B3]). The energetic boost could have positive effects on the fibroblasts and keratinocyte's proliferation and migration. Less Langerhans cells are present in aged skin where a cascade of regulatory and proinflammatory cytokines takes place ([@B64]; [@B16]). Ultraviolet radiation induces immunosuppression and tolerance on Langerhans cells, due the presence of TNF-a, prostaglandin PGE2, and IL-10 ([@B109]). However, a great quantity of ROS is induced by UVR, resulting in skin photoaging and inflammation ([@B112]; [@B6]). The mitochondria transfer to immune cells by PAMM or by the isolation of MSC's mitochondria repairs UVR damage and changes the cells from proinflammatory to immune regulatory ([@B19]; [@B84]). The interaction between mitochondria and immune cells in the skin is puzzling as it could induce an immune regulatory effect in Langerhans cells, however, it would help them to survive and proliferate. Mitochondria transfer/transplant to nerve cells has shown to have effects such as improving their activity, growth and viability ([@B26]). When Merkel cells are exposed to the sun, their cellular density increases in a process that accumulates with age, leading to carcinogenesis, especially in elderly white men ([@B99]; [@B32]). A loss in the perception, fromsoftouch to itching has been associated with aging (alloknesis). This problem is correlated with a low number of merkel cells ([@B45]). Merkel cells have a long-term permanence in the skin where the AMT/T would help them to stay viable for a longer period of time ([@B38]) ([Figure 1B](#F1){ref-type="fig"}).

Melanocytes interact and influence keratinocytes metabolism through melanosomes transfer. Melanocytes affected by aging play a crucial role in disseminating damaging factors among cells in the skin. Melanogenesis is a multistep process regulated by melanocortins (MSH) and adrenocorticotropins, leading to the control of the tyrosinase enzyme using [L]{.smallcaps}-tyrosine as a precursor ([@B132]; [@B141]). [L]{.smallcaps}-tyrosine is also a precursor of thyroid hormones which in turn regulate melanin pigmentation ([@B132]). There exist two major melanine variants: pheomelanin (red head and freckles) and eumelanin (dark haired individuals), depending on the MCR1 (melanocortin 1 receptor) gene regulation ([@B144]). The first has been associated with a higher prooxidant effect because its synthesis consumes cysteine and glutathione antioxidant ([@B11]). In this context, it has been hypothesized that stimulation of eumelanin has a protective effect on mtDNA copy number ([@B144]). However, interactions between mtDNA and pheomelanin/eumalin ratio have not been properly researched. It has been shown that Melanocytes are able to express senescence markers such as p16INK4A, HMGB1, in addition to having dysfunctional telomeres. Interestingly, aged melanocytes can induce telomere dysfunction and senescence in surrounding cells via CXCR3 activation and ROS production ([@B156]).

Melanocytes are sensitive to oxidative stress due to the pro-oxidant state induced during melanogenesis ([@B37]; [@B134]). This process is confined to the melanosomes, which protects the cell from oxidative damage ([@B37]). Interestingly, melanosomes switch from oxidative catabolism to anaerobic glycolysis, activating the pentose phosphate pathway in the keratinocytes and possibly protecting them from oxidative damage ([@B131], [@B130], [@B139]). It has been observed that Alpha-melanocyte-stimulating hormone (alpha-MSH) stimulates melanogenesis, thus leading to the protection of keratinocytes from UVR induced DNA and mtDNA damage ([@B17]). Mitochondria in melanocytes interact with melanosomes suggesting an induction of melanosome biogenesis and melanin production ([@B103]; [@B144]). Melanin protects cells and their mtDNA from stressors such as UVA, UVB and H~2~O~2~ ([@B147]). Both the reduction of aerobic metabolism and the protection of mtDNA damage by melanosome transfer from melanocytes to keratinocytes could prevent accelerated skin aging. It is possible that renewing the mitochondrial pool in both cells could have beneficial effects in reducing the damage of UVR and environmental factors.

Melatonin is a hormone product of the pineal gland that regulates the circadian rhythm. It has been observed that melatonin can be produced by epidermal and hair follicle keratinocytes ([@B74]; [@B137], [@B133]). Melatonin has ROS scavenging properties it promotes antioxidant and DNA repair mechanisms, inducing immune modulation and antitumor properties ([@B135]). Interestingly, melatonin can be transferred to mitochondria by the peptide transporter PEPT1/2. This improves the mitochondrial membrane potential by inhibiting the activation of the permeability pore, stimulating the activity of uncoupling proteins (UCPs), and inducing an increase in ATP production ([@B135]). Melatonin and its derivatives N1-acetyl-N2 -formyl-5-methoxykynurenine (AFMK) and N-acetyl serotonin (NAS) are expressed in the human skin and have shown antioxidant and antiapoptotic activity ([@B129]; [@B137]). The secretion of melatonin by the pineal gland declines with age ([@B56]) and possibly affects the presence and production of melatonin in the skin. Melatonin strongly interacts with mitochondria, protecting them from UVR, ROS, and aging damage. Mitochondria are also able to produce melatonin in the mitochondrial matrix ([@B56]; [@B148]). Understanding the relationship between melatonin, its derivatives and AMT/T is key to mitigating the loss of skin functionality during the aging process ([Figure 1B](#F1){ref-type="fig"}).

Mitochondria may also interact with melanocyte proliferation and tyrosinase activity as *in vitro* experiments have shown their inhibition in the presence of melatonin, a hormone that heavily relies on mitochondria and ROS signaling ([@B144]). This is how mitochondrial damage may contribute to an alteration of skin pigmentation and aging. Melanocyte degeneration, cell cycle arrest, and apoptosis have been associated with oxidative stress due to mitochondrial dysfunction in Vitiligo ([@B149]; [@B161]).

Mitochondria, as a modulator of skin pigmentation, play an important role in the initial protection against UVR ([@B144]). More pigmentation (more melanin) is inversely related to DNA lesions in humans. mtDNA damage is vastly seen in photoexposed skin, leading to cellular damage and death ([@B144]). Even though aging would eventually happen due to the shortening of the telomere caps in nuclear DNA and consequent senescence, UVR is a major key factor in aging pathogenesis. This "photoageing" needs to be clarified as many aspects have been studied over the years: collagen, mtDNA damage, increased ROS production, and others ([@B11]). Ultraviolet radiation causes inflammation that breaks down matrix proteins and the activation of the ROS signaling pathways. This activates NFkB and AP-1, which inhibits collagen formation while old collagen is being destroyed. mtDNA damage in photoexposed areas increases ROS production and may accelerate skin aging ([@B144]). Skin exposed to UVR causes deletions of mtDNA, increased up to tenfold, compared with sun-protected skin of the same individuals ([@B8]). In human skin, UVR-induced deletions were found to persist for years and their levels increased after cessation of UVR irradiation even in the absence of further exposures ([@B80]; [@B79]). As was mentioned before, there are differences in the composition of extracellular matrix of papillary and reticular dermis. They differ also in rate of cell division, contraction, and in expression of various collagens and proteoglycans. Fibroblasts are responsible for synthesizing all types of fibers and ground substance, but their function depends on the specific tissue compartment where they reside ([@B85]).

[@B87] seeded human skin fibroblasts into collagen gels to generate dermal equivalents. These cells were either derived from Kearns-Sayre syndrome patients, who constitutively carry large amounts of the UVR-inducible mitochondrial common deletion, or normal human volunteers ([@B87]). Human skin fibroblasts carrying large amounts of the UVR-inducible common deletion in their mitochondrial genome translate functional and structural alterations into the dermal equivalent.

Ultraviolet radiation damages skin cells, especially their genetic material, leading to cancer ([@B120]; [@B128]). Furthermore, UVR negatively affects mitochondria structure and function, thus leading to the generation of ROS and decreased ATP production ([@B120]). Interestingly, it has been reported that 1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3) induces an energy-conserving mechanism, which reduce UVR-DNA damage and skin carcinogenesis ([@B120]; [@B25]). This mechanism works by increasing glycolysis in the affected cells, arresting mTORC1 and growth, activating autophagy and inhibition of proliferation, and repairing mitochondria ([@B120]). This evidence could lead to a treatment of UVR harmed skin that includes the administration of mitochondria mixed with 1,25(OH)2D3. If 1,25(OH)2D3 is inducing an energy-conserving mechanism, it would be possible to use the AMT/T after the autophagic mechanism, to help cells restore their mitochondrial patrimony and even mix with the transferred mitochondria.

In several reports, human dermal fibroblasts in tissue culture showed that carbonylated proteins, a marker for severe and chronic oxidative stress, were elevated in the last third of life ([@B143]). Disturbance in the prooxidant-antioxidant balance causes oxidative stress that is associated with aging and senescence. ROS are mainly produced by mitochondria during normal metabolism. High ROS levels produced by dysfunctional mitochondria have been suggested as the main cause of aging ([@B7]).

Intrinsic changes in the aged fibroblast, as well as exposure to environmental insults, lead to a progressive increase in connective tissue damage. This is mediated by matrix metalloproteinases (MMPs) and a reduction in new collagen synthesis. As the connective tissue becomes progressively damaged, it eventually becomes a stimulator of reduced fibroblast synthetic function.

The fibroblast growth factor (FGF) has a relevant role in anti-aging therapy as it is related to collagen and elastin synthesis activation, which is responsible for skin resistance and elasticity, characteristics that are diminished with skin aging ([@B86]). The progressive decline in the antioxidant capacity associated with age results in increased production of reactive oxygen species from oxidative metabolism in skin cells ([@B44]), and diminished mitophagy ([@B59]) could be treated by AMT/T possibly in combination with other factors such as FGF.

Hair quality may be also considered as a marker of aging. Melanocytes and keratinocytes determine hair color and growth. It has been hypothesized that mtDNA damage increases oxidative stress in the context of an acquired base pair deletion and is responsible for hair graying ([@B144]). Hair loss is a marker of aging and may be related to nutrient deficiency, alopecia, and androgen stimulation. In non-balding regions, there is an increased cytoplasmic and mitochondrial expression of superoxide dismutase ([@B144]). This represents a protective mechanism that promotes oxidative resistance and a repair function. Although very important questions need to be answered regarding AMT/T, hypothesizing that isolated mitochondria could be internalized by melanocytes to help cells produce energy more efficiently, less ROS ([@B162]), and ultimately fewer mutations are plausible.

It is our belief that the procedure for delivering mitochondria by AMT/T to the skin and its cells is key to inducing its repair mechanisms. The kind of mitochondria, their origin, and if they have been modified in any way should be considered when evaluating its regenerative capacities ([@B20]; [@B97]). After defining determining the best mitochondria, one method of delivering them could be to transfer it ex vivo to patient's skin cells by MitoCeption and reintroducing them in the affected area ([@B21], [@B20]; [@B19]; [@B97]). Delivering mitochondria with needles, especially microneedles ([@B146]), could be an option, however, special attention should be made as skin is very thin in some areas and it is important to traverse the stratum corneum ([@B76]). Microneedle patches have shown to be painless and easy to use, with modulable parameters desirable for drug delivery ([@B115]). Microneedle patches could be designed for mitocondria delivery and tested together with *in vivo* experiments. As previously mentioned, mitochondria doesn't seem to need encapsulation or additives to be uptaken by cells, however, how mitochondria is going to be suspended or if an emulsion or microemulsion ([@B54]) is needed to traverse the stratum corneum, will need further research ([Figure 1B](#F1){ref-type="fig"}).

Conclusion {#S6}
==========

Environmental factors besides time can induce the acceleration of aging and the mitochondrial dysfunction of skin ([@B108]; [@B156]; [@B53]). Exposure to these factors, such as sunlight, could be prevented by sunscreens or simply by limiting the exposition to UVR. However, they are difficult to repair once damage is present ([@B62]). Even if mitochondrial dysfunction is mitigated through intracellular mechanisms, such as the quality control process ([@B145]), damages still accumulate with time, decreasing the overall life-span of a person ([@B88]; [@B102]). Based on these observations, it is plausible to propose AMT/T as a way to enrich the endogenous pool with healthy mitochondria, even if questions about intracellular interactions and transfer effects still remain today ([@B3]).

Skin function relies on many cellular and intracellular mechanisms, among them mitochondria integrity. Many of the mechanisms contributing to skin aging are not fully understood; nevertheless, it is clear that mitochondria play an important role within a complex network ([@B13]; [@B62]; [@B53]). Among them, mitochondria metabolism of substances like melanin maintain intracellular homeostasis by photoprotective processes ([@B103]; [@B149]). As a result, the accumulation of small abnormalities or deficits may lead to larger negative effects on the skin and its components if cells endogenous mitochondria is not treated.

The skin is a complex tissue of layers and cells that play different functions ([@B151]). Skin cells and structures suffer differently after being exposed to aging inducing factors such as UVR, where mitochondria are one of the most affected organelles ([@B62]). As seen in literature, the AMT/T is able to repair damage, especially hypoxia, in many cells and tissues ([@B9]; [@B152]; [@B20]; [@B42]; -- Methods for the intercellular transfer of isolated mitochondria in recipient cells -- Google Patents). AMT/T has shown regenerative effects *in vitro* and *in vivo*. Isolated mitochondria could be an interesting therapeutic agent of choice to neurodegenerative and cardiovascular diseases ([@B93]; [@B18]). Here we propose the hypothesis that AMT/T would help the skin and its cells to persist or recover after aging inducing factors exposition and be viable for a longer alone or as a complement to current standards of care and prevention.

Still many challenges need to be overcome in order to generalize the application of mitochondria as a therapeutic agent to accelerate aging and disease. What is the effect of isolated mitochondria from different tissues on different tissues, do they behave the same. Different methods of administration must be tested in order to find the best for each application ([@B33]; [@B117]). How to protect the isolated mitochondria during the process of transfer/transplant, are there mitochondria that are more resistant than others as it seems that some can normally exist outside cells without a cover membrane ([@B1]; [@B10]; [@B92]). This article intends to present one of the many aspects in which mitochondria could be used as an universal treatment for cell damage and aging.
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